Elevation Point Wealth Partners LLC Buys 30,746 Shares of Astrazeneca Plc $AZN

Elevation Point Wealth Partners LLC raised its stake in shares of Astrazeneca Plc (NYSE:AZN) by 212.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 45,217 shares of the company’s stock after purchasing an additional 30,746 shares during the quarter. Elevation Point Wealth Partners LLC’s holdings in Astrazeneca were worth $8,914,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Triumph Capital Management bought a new position in shares of Astrazeneca in the 3rd quarter worth $25,000. MV Capital Management Inc. bought a new stake in shares of Astrazeneca during the 4th quarter worth $26,000. Bangor Savings Bank grew its position in Astrazeneca by 102.7% in the fourth quarter. Bangor Savings Bank now owns 304 shares of the company’s stock worth $28,000 after acquiring an additional 154 shares in the last quarter. Eagle Bay Advisors LLC bought a new position in Astrazeneca in the fourth quarter valued at $30,000. Finally, YANKCOM Partnership purchased a new stake in Astrazeneca during the fourth quarter valued at about $31,000. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on AZN. Wall Street Zen raised Astrazeneca from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Barclays reissued a “buy” rating on shares of Astrazeneca in a report on Monday, June 1st. Sanford C. Bernstein restated a “buy” rating on shares of Astrazeneca in a research report on Monday, May 4th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Friday, June 26th. Finally, JPMorgan Chase & Co. reiterated a “buy” rating on shares of Astrazeneca in a research report on Tuesday. Fourteen research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Astrazeneca currently has a consensus rating of “Moderate Buy” and an average target price of $205.33.

Astrazeneca Price Performance

AZN opened at $194.96 on Friday. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71. The stock’s 50 day simple moving average is $183.91 and its 200 day simple moving average is $187.76. The firm has a market cap of $302.36 billion, a price-to-earnings ratio of 29.27, a PEG ratio of 1.49 and a beta of 0.24. Astrazeneca Plc has a 1 year low of $137.23 and a 1 year high of $212.71.

Astrazeneca (NYSE:AZN) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The firm had revenue of $15.29 billion during the quarter, compared to the consensus estimate of $14.93 billion. As a group, analysts predict that Astrazeneca Plc will post 10.28 earnings per share for the current year.

Trending Headlines about Astrazeneca

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: AstraZeneca announced a strategic collaboration with Abbisko Therapeutics to advance a Phase I/II clinical trial of lumipodlin (ABSK043) combined with Tagrisso for non-small cell lung cancer, adding another pipeline development opportunity. Article Title
• Positive Sentiment: AZN’s cancer drug Enhertu won another EU approval for HER2-positive solid tumors, extending its commercial footprint and reinforcing investor confidence in the company’s oncology franchise. Article Title
• Positive Sentiment: Goldman Sachs and Bank of America both reaffirmed “buy” ratings on AstraZeneca, while Erste Group raised its FY2026 EPS estimate, signaling continued analyst confidence in earnings power. Article Title
• Positive Sentiment: Separate style-score coverage from Zacks highlighted AZN as both a strong value stock and a strong momentum stock, which may have supported buying interest. Article Title
• Neutral Sentiment: MarketBeat noted that AstraZeneca’s shares have recently traded below some valuation-based fair value estimates, suggesting the stock still screens as expensive despite the recent rally.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.